Table 1.

Rosiglitazone (1 µM) and 15d-PGJ₂ (10 µM) inhibit PMA- and MPs-evoked cytokine release in all cell types

	% inhibition of MPs 10 µg·mL−1		% inhibition of PMA 10−7 M
	TNF-α	IL-6	TNF-α	IL-6
Monocytes (n = 5)
Rosi	27 ± 1	60 ± 6**	62 ± 2§§	58 ± 3
15d-PGJ2	92 ± 1°°	96 ± 1°°	95 ± 2°°	82 ± 4°°
MDM (n = 5)
Rosi	28 ± 5	30 ± 3	40 ± 8	42 ± 7
15d-PGJ2	40 ± 6	54 ± 5°°	52 ± 3	58 ± 5

Cells were pretreated with (or without) PPARγ agonists for 1 h and then stimulated by PMA or MPs for 24 h; the percentage of cytokine release inhibition produced by each agonist was calculated. Rosi: rosiglitazone. Data are expressed as mean + SEM of five experiments.

^**P < 0.01 versus TNF-α

^°°P < 0.01 versus rosiglitazone

^§§P < 0.01 versus MPs.